STE - Earnings announcements

Full year fiscal 2026 revenue from continuing operations increased 9%; constant currency organic revenue growth was 7% Full year fiscal 2026 as reported diluted EPS from continuing operations increased to $7.93; adjusted EPS per diluted share increased to $10.17Board approves new $1 billion share repurchase program DUBLIN, IRELAND, May 11, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2026 fourth quarter and full year ended March 31, 2026. Total revenue from continuing operations for the fourth quarter of fiscal 2026 increased 7% to $1.6 billion compared with $1.5 billion in the fourth quarter of fiscal 2025. C

DUBLIN, IRELAND, April 21, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2026 fourth quarter and full year results at 9:00 a.m. ET on May 12, 2026. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after the U.S. market closes on May 11, 2026. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on May 12, 2026, eit

Total revenue from continuing operations increased 9%; constant currency organic revenue grew 8% As reported EPS from continuing operations increased to $1.96; adjusted EPS increased to $2.53Fiscal 2026 outlook maintained DUBLIN, IRELAND, Feb. 04, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2026 third quarter ended December 31, 2025. Total revenue from continuing operations for the third quarter of fiscal 2026 increased 9% to $1.5 billion compared with $1.4 billion in the third quarter of fiscal 2025. Constant currency organic revenue growth from continuing operations for the third quarter was 8%. "We are pl

DUBLIN, IRELAND, Jan. 21, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2026 third quarter results at 9:00 a.m. ET on February 5, 2026. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after the U.S. market closes on February 4, 2026. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on February 5, 2026, either

Total revenue from continuing operations increased 10%; constant currency organic revenue grew 9%As reported EPS from continuing operations increased to $1.94; adjusted EPS increased to $2.47Fiscal 2026 constant currency organic revenue, EPS and free cash flow outlook increased DUBLIN, IRELAND , Nov. 05, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2026 second quarter ended September 30, 2025. Total revenue from continuing operations for the second quarter of fiscal 2026 increased 10% to $1.5 billion compared with $1.3 billion in the second quarter of fiscal 2025. Constant currency organic revenue growth from

DUBLIN, IRELAND, Oct. 21, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2026 second quarter results at 9:00 a.m. ET on November 6, 2025. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-800-715-9871 in the United States or 1-646-307-1963 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after the U.S. market closes on November 5, 2025. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on November 6, 2025, either

Long-time CFO Michael J. Tokich to be succeeded by Karen L. Burton,  Chief Accounting Officer DUBLIN, IRELAND, Aug. 06, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that Michael J. Tokich, Senior Vice President and Chief Financial Officer (CFO), is stepping down from his role following seventeen years as CFO. The transition from Tokich to Karen L. Burton, currently Vice President and Chief Accounting Officer (CAO), will occur on August 18, 2025. Thereafter, Tokich will become Senior Financial Advisor, reporting to the CEO. "Mike's contributions over the past 25 years at STERIS have been instrumental in our growth and success," said Dan Care

Total revenue from continuing operations increased 9%; constant currency organic revenue grew 8% As reported EPS from continuing operations increased to $1.79; adjusted EPS increased to $2.34Fiscal 2026 revenue and free cash flow outlook updated DUBLIN, IRELAND, Aug. 06, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2026 first quarter ended June 30, 2025. Total revenue from continuing operations for the first quarter of fiscal 2026 increased 9% to $1.4 billion compared with $1.3 billion in the first quarter of fiscal 2025. Constant currency organic revenue growth from continuing operations for the first quarte

DUBLIN, IRELAND, July 22, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2026 first quarter results at 9:00 a.m. ET on August 7, 2025. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after the U.S. market closes on August 6, 2025. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on August 7, 2025, either at ww

Full year fiscal 2025 revenue from continuing operations increased 6%; constant currency organic revenue growth was 6% Full year fiscal 2025 as reported diluted EPS from continuing operations increased to $6.16; adjusted EPS per diluted share increased to $9.22Fiscal 2026 outlook provided DUBLIN, IRELAND, May 14, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2025 fourth quarter and full year ended March 31, 2025. Total revenue from continuing operations for the fourth quarter of fiscal 2025 increased 4% to $1.5 billion compared with $1.4 billion in the fourth quarter of fiscal 2024. Constant currency organic re

DUBLIN, IRELAND, April 22, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2025 fourth quarter and full year financial results at 9:00 a.m. ET on May 15, 2025. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after the U.S. market closes on May 14, 2025. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on May 15,

Total revenue from continuing operations increased 6%; constant currency organic revenue grew 6% As reported diluted EPS from continuing operations increased to $1.75; adjusted EPS increased to $2.32Fiscal 2025 outlook updated DUBLIN, IRELAND, Feb. 05, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2025 third quarter ended December 31, 2024. Total revenue from continuing operations for the third quarter of fiscal 2025 increased 6% to $1.4 billion compared with $1.3 billion in the third quarter of fiscal 2024. Constant currency organic revenue from continuing operations for the third quarter also increased 6%. "

DUBLIN, IRELAND , Jan. 22, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2025 third quarter financial results at 9:00 a.m. ET on February 6, 2025. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after the U.S. market closes on February 5, 2025. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on February 6, 2

Total revenue from continuing operations increased 7%; constant currency organic revenue grew 7%As reported diluted EPS from continuing operations increased to $1.51; adjusted EPS increased to $2.14Fiscal 2025 outlook reiterated DUBLIN, IRELAND, Nov. 06, 2024 (GLOBE NEWSWIRE) --  - STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2025 second quarter ended September 30, 2024. Total revenue from continuing operations for the second quarter of fiscal 2025 increased 7% to $1.3 billion compared with $1.2 billion in the second quarter of fiscal 2024. Constant currency organic revenue from continuing operations for the second quarter increased 7

DUBLIN, IRELAND, Oct. 23, 2024 (GLOBE NEWSWIRE) --  STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2025 second quarter financial results at 9:00 a.m. ET on November 7, 2024. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.   A press release detailing financial results will be issued after the U.S. market closes on November 6, 2024. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on November 7,

Total revenue from continuing operations increased 8%; constant currency organic revenue grew 6%As reported EPS from continuing operations increased to $1.41; adjusted EPS increased to $2.03Fiscal 2025 outlook reiterated DUBLIN, IRELAND , Aug. 06, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2025 first quarter ended June 30, 2024. Total revenue from continuing operations for the first quarter of fiscal 2025 increased 8% to $1.3 billion compared with $1.2 billion in the first quarter of fiscal 2024. Constant currency organic revenue from continuing operations for the first quarter increased 6%. "We are ple

DUBLIN, IRELAND, July 23, 2024 (GLOBE NEWSWIRE) --  STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2025 first quarter financial results at 9:00 a.m. ET on August 7, 2024. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.   A press release detailing financial results will be issued after the U.S. market closes on August 6, 2024. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on August 7, 2024,

Total fiscal 2024 revenue increased 12% to $5.5 billionTotal fiscal 2024 U.S. GAAP earnings per diluted share of $3.81; adjusted earnings per diluted share increased to $8.83Targeted restructuring plan announced DUBLIN, IRELAND , May 08, 2024 (GLOBE NEWSWIRE) --  STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2024 fourth quarter ended March 31, 2024. Total revenue for the fourth quarter of fiscal 2024 increased 10% to $1.5 billion compared with $1.4 billion in the fourth quarter of fiscal 2023. Constant currency organic revenue from continuing operations for the fourth quarter increased 7% to $1.4 billion compared with $1.3 billion in

DUBLIN, IRELAND, April 24, 2024 (GLOBE NEWSWIRE) --  STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2024 fourth quarter and full year financial results at 9:00 a.m. ET on May 9, 2024. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.   A press release detailing financial results will be issued after the U.S. market closes on May 8, 2024. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on May 9,

Third quarter revenue increases 15% as reported; 10% constant currency organicAs reported diluted earnings per share increased to $1.42; adjusted earnings per share increased to $2.22Fiscal 2024 outlook updated DUBLIN, IRELAND, Feb. 07, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2024 third quarter ended December 31, 2023. Revenue as reported for the quarter increased 15% to $1.40 billion compared with $1.22 billion in the third quarter of fiscal 2023. Constant currency organic revenue (see Non-GAAP Financial Measures) increased 10% for the third quarter of fiscal 2024 as compared to the third quarter of fisca

DUBLIN, IRELAND, Jan. 23, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2024 third quarter financial results at 9:00 a.m. ET on February 8, 2024. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.   A press release detailing financial results will be issued after the U.S. market closes on February 7, 2024. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on November 8, 2

Second quarter revenue growth of 12% as reported and 8% constant currency organicAs reported diluted earnings per share increased to $1.16; adjusted earnings increased to $2.03Fiscal 2024 outlook maintained DUBLIN, IRELAND, Nov. 07, 2023 (GLOBE NEWSWIRE) --  STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2024 second quarter ended September 30, 2023. Revenue as reported for the quarter increased 12% to $1.34 billion compared with $1.20 billion in the second quarter of fiscal 2023. Constant currency organic revenue (see Non-GAAP Financial Measures) increased 8% for the second quarter of fiscal 2024 as compared to the second quarter of

DUBLIN, IRELAND, Oct. 24, 2023 (GLOBE NEWSWIRE) --  STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2024 second quarter financial results at 9:00 a.m. ET on November 8, 2023. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.   A press release detailing financial results will be issued after the U.S. market closes on November 7, 2023. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on November 8,

DUBLIN, IRELAND, Aug. 02, 2023 (GLOBE NEWSWIRE) --  STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced that it has completed the previously announced acquisition of the surgical instrumentation, laparoscopic instrumentation and sterilization container assets from BD (Becton, Dickinson and Company) (NYSE:BDX). "We are pleased to announce the closing of this acquisition, as the brands we are adding will strengthen, complement and expand STERIS's product offerings within our Healthcare segment," said Dan Carestio, President and Chief Executive Officer of STERIS. "We welcome these teams to STERIS and look forward to working together to enhance our value to our Customers." Laza

First quarter revenue growth of 11% as reported and constant currency organicAs reported diluted earnings per share increased to $1.25; adjusted earnings increased to $2.00Fiscal 2024 outlook updated to reflect acquisition of BD surgical instrumentation assets DUBLIN, IRELAND, Aug. 01, 2023 (GLOBE NEWSWIRE) --  STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2024 first quarter ended June 30, 2023. Revenue as reported for the quarter increased 11% to $1.28 billion compared with $1.16 billion in the first quarter of fiscal 2023. Constant currency organic revenue (see Non-GAAP Financial Measures) also increased 11% for the first quarter o

DUBLIN, IRELAND, July 19, 2023 (GLOBE NEWSWIRE) --  STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2024 first quarter financial results at 9:00 a.m. ET on August 2, 2023. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.   A press release detailing financial results will be issued after the U.S. market closes on August 1, 2023. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on August 2, 2023,

Divestiture Advances BD2025 Strategy to Simplify Portfolio  and Focus on Higher-Growth Markets FRANKLIN LAKES, N.J., June 20, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that it has signed a definitive agreement to sell its Surgical Instrumentation platform to STERIS (NYSE:STE) for $540 million. The divestiture will include V. Mueller™, Snowden-Pencer™ and Genesis™ branded products and three manufacturing facilities located in St. Louis, Mo., Cleveland, Ohio and Tuttlingen, Germany. Approximat

A natural extension for STERIS in the operating room and sterile processing departmentA primarily consumables product portfolioTransaction expected to close by September 30, 2023 DUBLIN, IRELAND , June 20, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced that the Company has signed a definitive agreement to purchase the surgical instrumentation, laparoscopic instrumentation and sterilization container assets from Becton, Dickinson and Company (NYSE:BDX) ("BD") for $540 million ("the Transaction"). STERIS anticipates that the acquisition will qualify for a tax benefit related to tax deductible goodwill, with a present value of approximately $60 mi

Fourth quarter as reported revenue increased 14%; 16% constant currency organic revenue growthFourth quarter as reported earnings per share of $1.88; adjusted EPS of $2.30Fiscal 2024 Outlook Provided DUBLIN, IRELAND , May 10, 2023 (GLOBE NEWSWIRE) --  STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2023 fourth quarter and full year ended March 31, 2023. Revenue as reported for the quarter increased 14% to $1.38 billion compared with $1.21 billion in the fourth quarter of fiscal 2022. Constant currency organic revenue (see Non-GAAP Financial Measures) increased 16% for the fourth quarter of fiscal 2023 as compared to the fourth quarter of

DUBLIN, IRELAND, April 24, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2023 fourth quarter and full year financial results at 9:00 a.m. ET on May 11, 2023. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.   A press release detailing financial results will be issued after the U.S. market closes on May 10, 2023. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on May

As reported revenue increased 1%; 7% constant currency organic revenue growthAs reported earnings per share of $1.24; adjusted EPS of $2.02Updated outlook provided DUBLIN, IRELAND, Feb. 08, 2023 (GLOBE NEWSWIRE) --  STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2023 third quarter ended December 31, 2022. Revenue as reported for the quarter increased 1% to $1.22 billion compared with $1.21 billion in the third quarter of fiscal 2022. Constant currency organic revenue (see Non-GAAP Financial Measures) increased 7% for the third quarter of fiscal 2023 as compared to the third quarter of fiscal 2022.   "We delivered 7% constant currency or

DUBLIN, IRELAND, Jan. 25, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2023 third quarter financial results at 10:00 a.m. ET on February 9, 2023. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.   A press release detailing third quarter financial results will be issued after the U.S. market closes on February 8, 2023. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET o

As reported revenue was flat; 7% constant currency organic revenue growthAs reported loss per share of ($3.15); adjusted EPS of $1.99As reported loss includes an impairment charge of $490.6 million related to the Dental segment DUBLIN, IRELAND, Nov. 09, 2022 (GLOBE NEWSWIRE) --  STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2023 second quarter ended September 30, 2022. Revenue as reported for the quarter was flat at $1.2 billion compared with $1.2 billion in the second quarter of fiscal 2022. Constant currency organic revenue (see Non-GAAP Financial Measures) increased 7% for the second quarter of fiscal 2023 as compared to the secon

DUBLIN, IRELAND, Oct. 25, 2022 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2023 second quarter financial results at 10:00 a.m. ET on November 10, 2022. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.   A press release detailing second quarter financial results will be issued after the U.S. market closes on November 9, 2022. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. E

First quarter revenue increases 19% as reported; 6% constant currency organicAs reported EPS of $1.10; adjusted EPS of $1.90Updated outlook provided DUBLIN, IRELAND, Aug. 02, 2022 (GLOBE NEWSWIRE) --  STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2023 first quarter ended June 30, 2022. Revenue as reported for the quarter increased 19% to $1.2 billion compared with $968.4 million in the first quarter of fiscal 2022. Constant currency organic revenue (see Non-GAAP Financial Measures) increased 6% for the first quarter of fiscal 2023 as compared to the first quarter of fiscal 2022.   "We are pleased with our operational performance in the

DUBLIN, IRELAND, July 20, 2022 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2023 first quarter financial results at 10:00 a.m. ET on August 3, 2022. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.   A press release detailing first quarter financial results will be issued after the U.S. market closes on August 2, 2022. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on

Fourth quarter revenue increases 39% as reported; 11% constant currency organicAs reported EPS of $0.52; adjusted EPS of $2.04Company provides FY23 outlook DUBLIN, IRELAND, May 11, 2022 (GLOBE NEWSWIRE) --  STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2022 fourth quarter ended March 31, 2022. Revenue as reported for the quarter increased 39% to $1.2 billion compared with $873.5 million in the fourth quarter of fiscal 2021. Constant currency organic revenue (see Non-GAAP Financial Measures) increased 11% for the fourth quarter of fiscal 2022 as compared to the fourth quarter of fiscal 2021.   "We are pleased to end the year with st

DUBLIN, IRELAND, April 25, 2022 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2022 fourth quarter and full year financial results at 10:00 a.m. ET on May 12, 2022. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.   A press release detailing fourth quarter and full year financial results will be issued after the U.S. market closes on May 11, 2022. For those unable to listen to the conference call live, a replay will be available begin

Third quarter revenue increases 49% as reported; 9% constant currency organicAs reported EPS of $1.42; adjusted EPS of $2.12Outlook for FY22 raised DUBLIN, IRELAND, Feb. 08, 2022 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2022 third quarter ended December 31, 2021. Revenue as reported for the quarter increased 49% to $1.2 billion compared with $808.9 million in the third quarter of fiscal 2021. Constant currency organic revenue (see Non-GAAP Financial Measures) increased 9% for the third quarter of fiscal 2022 as compared to the third quarter of fiscal 2021.   "We are pleased with our performance in the third qua

DUBLIN, IRELAND, Jan. 25, 2022 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2022 third quarter financial results at 10:00 a.m. ET on February 9, 2022. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.   A press release detailing third quarter financial results will be issued after the U.S. market closes on February 8, 2022. For those unable to listen to the conference call live, a replay will be available beginning at 12:

Second quarter revenue increases 58% as reported; 12% constant currency organicAs reported EPS of $0.69; adjusted EPS of $1.99Company reiterates fiscal 2022 outlook DUBLIN, IRELAND , Nov. 02, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2022 second quarter ended September 30, 2021. Revenue as reported for the quarter increased 58% to $1,197 million compared with $756 million in the second quarter of fiscal 2021. Constant currency organic revenue (see Non-GAAP Financial Measures) increased 12% for the second quarter of fiscal 2022 as compared to the second quarter of fiscal 2021.   "We continue to benef

Dublin, Ireland, Oct. 20, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2022 second quarter financial results at 10:00 a.m. ET on November 3, 2021. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.   A press release detailing second quarter financial results will be issued after the U.S. market closes on November 2, 2021. For those unable to listen to the conference call live, a replay will be available beginning at 12:00

First quarter revenue increases 45% as reported; 21% constant currency organicCantel Medical integration on trackCompany increases outlook and raises quarterly dividend DUBLIN, IRELAND, Aug. 09, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2022 first quarter ended June 30, 2021. Revenue as reported for the quarter increased 45% to $968.4 million compared with $668.9 million in the first quarter of fiscal 2021. Constant currency organic revenue (see Non-GAAP Financial Measures) increased 21% for the first quarter of fiscal 2022 as compared to the first quarter of fiscal 2021, which was negatively impacted by t

DUBLIN, IRELAND , July 27, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2022 first quarter financial results at 10:00 a.m. ET on Tuesday, August 10, 2021. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing first quarter financial results will be issued after the U.S. market closes on Monday, August 9, 2021. For those unable to listen to the conference call live, a replay will be available beginning at 12

Fourth quarter revenue increases 6% as reported; full year increases 3% as reportedFull year earnings per diluted share of $4.63 on a U.S. GAAP basis and $6.17 on an adjusted basis on effective tax rates of 23.3% and 20.7%, respectivelyCompany provides outlook for fiscal 2022 including Cantel Medical DUBLIN, IRELAND, May 18, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2021 fourth quarter ended March 31, 2021. Revenue as reported for the quarter increased 6% to $873.5 million compared with $823.0 million in the fourth quarter of fiscal 2020, with growth in all three segments. Constant currency organic rev

Third quarter revenue increases 4% as reported; 1% constant currency organic Third quarter earnings per diluted share increase to $1.33 on a U.S. GAAP basis and $1.73 on an adjusted basisIncreased free cash flow driven by net income growth and working capital improvements DUBLIN, IRELAND , Feb. 02, 2021 (GLOBE NEWSWIRE) --  STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2021 third quarter ended December 31, 2020.  Revenue as reported for the quarter increased 4% to $808.9 million compared with $774.3 million in the third quarter of fiscal 2020, with growth in all three segments. Constant currency organic revenue (see Non-GAAP Financia